JP2020529405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529405A5 JP2020529405A5 JP2020505150A JP2020505150A JP2020529405A5 JP 2020529405 A5 JP2020529405 A5 JP 2020529405A5 JP 2020505150 A JP2020505150 A JP 2020505150A JP 2020505150 A JP2020505150 A JP 2020505150A JP 2020529405 A5 JP2020529405 A5 JP 2020529405A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- alkyl
- optionally
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 195
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 73
- 208000035475 disorder Diseases 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 33
- -1 hydrate Substances 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 125000001475 halogen functional group Chemical group 0.000 claims description 26
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- 108010034143 Inflammasomes Proteins 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 8
- 208000035690 Familial cold urticaria Diseases 0.000 claims description 8
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 8
- 208000020832 chronic kidney disease Diseases 0.000 claims description 8
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000000543 intermediate Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 4
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000024777 Prion disease Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 208000007153 proteostasis deficiencies Diseases 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 241000287463 Phalacrocorax Species 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 37
- 0 C*(Cc1cnccn1)=C Chemical compound C*(Cc1cnccn1)=C 0.000 description 10
- 201000003274 CINCA syndrome Diseases 0.000 description 3
- 206010064568 Chronic infantile neurological cutaneous and articular syndrome Diseases 0.000 description 3
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002314 neuroinflammatory effect Effects 0.000 description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- CAWAHTZCIOIESJ-QMMMGPOBSA-N C[C@@H](Cc1c(C#N)nccn1)N(C)C Chemical compound C[C@@H](Cc1c(C#N)nccn1)N(C)C CAWAHTZCIOIESJ-QMMMGPOBSA-N 0.000 description 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023094466A JP2023116627A (ja) | 2017-07-31 | 2023-06-08 | 選択的ｎｌｒｐ３インフラマソーム阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1712282.1A GB201712282D0 (en) | 2017-07-31 | 2017-07-31 | Selective inhibitors of NLRP3 inflammasome |
| GB1712282.1 | 2017-07-31 | ||
| PCT/EP2018/070799 WO2019025467A1 (en) | 2017-07-31 | 2018-07-31 | SELECTIVE INHIBITORS OF INFLAMMASOME NLRP3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023094466A Division JP2023116627A (ja) | 2017-07-31 | 2023-06-08 | 選択的ｎｌｒｐ３インフラマソーム阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529405A JP2020529405A (ja) | 2020-10-08 |
| JP2020529405A5 true JP2020529405A5 (enExample) | 2021-09-02 |
| JP7357602B2 JP7357602B2 (ja) | 2023-10-06 |
Family
ID=59778868
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505150A Active JP7357602B2 (ja) | 2017-07-31 | 2018-07-31 | 選択的ｎｌｒｐ３インフラマソーム阻害剤 |
| JP2023094466A Withdrawn JP2023116627A (ja) | 2017-07-31 | 2023-06-08 | 選択的ｎｌｒｐ３インフラマソーム阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023094466A Withdrawn JP2023116627A (ja) | 2017-07-31 | 2023-06-08 | 選択的ｎｌｒｐ３インフラマソーム阻害剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12247011B2 (enExample) |
| EP (1) | EP3661921B1 (enExample) |
| JP (2) | JP7357602B2 (enExample) |
| KR (1) | KR102704546B1 (enExample) |
| CN (1) | CN111356680B (enExample) |
| AU (1) | AU2018311198B2 (enExample) |
| BR (1) | BR112020001713A2 (enExample) |
| CA (1) | CA3070515A1 (enExample) |
| DK (1) | DK3661921T3 (enExample) |
| EA (1) | EA202090419A1 (enExample) |
| ES (1) | ES2968669T3 (enExample) |
| FI (1) | FI3661921T3 (enExample) |
| GB (1) | GB201712282D0 (enExample) |
| HR (1) | HRP20231690T1 (enExample) |
| HU (1) | HUE065337T2 (enExample) |
| IL (1) | IL272052B2 (enExample) |
| LT (1) | LT3661921T (enExample) |
| MX (1) | MX2020001218A (enExample) |
| PL (1) | PL3661921T3 (enExample) |
| PT (1) | PT3661921T (enExample) |
| RS (1) | RS65100B1 (enExample) |
| SG (1) | SG11202000325UA (enExample) |
| SI (1) | SI3661921T1 (enExample) |
| SM (1) | SMT202400006T1 (enExample) |
| TW (1) | TWI810198B (enExample) |
| WO (1) | WO2019025467A1 (enExample) |
| ZA (1) | ZA202000425B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2561540A (en) | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| BR112021000964A2 (pt) | 2018-07-25 | 2021-04-20 | Novartis Ag | inibidores do inflamassoma de nlrp3 |
| EP3914351A1 (en) | 2019-01-25 | 2021-12-01 | Nodthera Limited | Carbamate derivatives and uses thereof |
| EP3956342A4 (en) | 2019-02-15 | 2023-05-24 | Triterpenoid Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR INHIBITION OF NLRP3 INFLAMMASOME AND/OR LON PROTEASE |
| US20220220480A1 (en) | 2019-04-17 | 2022-07-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders |
| CN110372499B (zh) * | 2019-05-20 | 2022-05-20 | 南京中澳转化医学研究院有限公司 | Carm1小分子抑制剂及其应用 |
| US12168643B2 (en) | 2019-06-19 | 2024-12-17 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| JP2023501319A (ja) * | 2019-11-07 | 2023-01-18 | インフレイゾーム リミテッド | 神経変性疾患の処置および予防 |
| JP7691997B2 (ja) * | 2020-03-27 | 2025-06-12 | ヴィフォー （インターナショナル） リミテッド | メチル２－フルオロアクリレートの合成 |
| WO2021198511A1 (en) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of sars-cov-2 infection |
| US12428391B2 (en) | 2020-06-11 | 2025-09-30 | Cisen Pharmaceutical Co., Ltd | Dimethylsulfoximine derivative |
| WO2022008597A1 (en) | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
| WO2022084300A1 (en) | 2020-10-20 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and monitoring form of coronavirus infection |
| CN113200825A (zh) * | 2021-04-27 | 2021-08-03 | 上海立科化学科技有限公司 | 一种2-(4-苯甲氧基苯基)乙醇的制备方法 |
| CA3219597A1 (en) * | 2021-06-23 | 2022-12-29 | F. Hoffmann-La Roche Ag | Novel process |
| CN115616216B (zh) * | 2021-07-15 | 2025-08-12 | 华南理工大学 | 抑制或阻断faah与nlrp3之间相互作用的制剂的用途 |
| CN116143753B (zh) * | 2021-08-26 | 2025-07-08 | 瑞石生物医药有限公司 | Nlrp3抑制剂化合物 |
| CN113831293A (zh) * | 2021-11-08 | 2021-12-24 | 河南科技大学 | 一种氨基甲酸酯化合物的制备方法 |
| CN116496255A (zh) * | 2022-01-27 | 2023-07-28 | 杭州邦顺制药有限公司 | Nlrp3抑制剂 |
| JP2025533089A (ja) | 2022-10-04 | 2025-10-03 | ノッドセラ リミテッド | カルバメート誘導体の形態および関連用途 |
| EP4598631A1 (en) * | 2022-10-05 | 2025-08-13 | Nodthera Limited | Methods of preparing carbamate derivatives |
| WO2024249539A1 (en) | 2023-06-02 | 2024-12-05 | Merck Sharp & Dohme Llc | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
| WO2024261302A1 (en) | 2023-06-22 | 2024-12-26 | Institut National de la Santé et de la Recherche Médicale | Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders |
| WO2025153532A1 (en) * | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025191141A1 (en) * | 2024-03-15 | 2025-09-18 | NodThera Limited | Methods of preparing carbamate derivatives |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH281646A (de) | 1950-03-16 | 1952-03-15 | Ag J R Geigy | Verfahren zur Herstellung eines chromierbaren Farbstoffes. |
| CH281649A (de) | 1950-03-16 | 1952-03-15 | Ag J R Geigy | Verfahren zur Herstellung eines chromierbaren Farbstoffes. |
| GB789445A (en) | 1953-05-26 | 1958-01-22 | Columbia Southern Chem Corp | Carboxy-alkyl n-substituted phenyl carbamate and herbicidal compositions thereof |
| GB1241917A (en) | 1968-11-27 | 1971-08-04 | Sumitomo Chemical Co | (n-phenylcarbamoyloxy)-alkanoate derivatives and anti-microbial compositions comprising them |
| GB1333209A (en) | 1970-05-22 | 1973-10-10 | Ici Ltd | Method of regulating plant growlth |
| JPS5424870A (en) | 1977-07-25 | 1979-02-24 | Mitsubishi Chem Ind Ltd | Oxazolidine-2,4-diones and agricultural and horticultural fungicides containing them |
| DE2926049A1 (de) | 1979-06-28 | 1981-01-08 | Basf Ag | M-anilidurethane und diese enthaltende herbizide |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ATE69051T1 (de) | 1985-10-11 | 1991-11-15 | Sagami Chem Res | Oxazolidindionabkoemmlinge, deren herstellungsverfahren und unkrautvertilgungsmittel, die diese enthalten. |
| US4818899A (en) | 1986-12-03 | 1989-04-04 | Minnesota Mining And Manufacturing Company | Second harmonic generation by carbamic acid derivatives |
| JP2763904B2 (ja) | 1988-02-17 | 1998-06-11 | 財団法人相模中央化学研究所 | オキサゾリジン誘導体およびその製造方法 |
| US5223499A (en) | 1989-05-30 | 1993-06-29 | Merck & Co., Inc. | 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists |
| US5614498A (en) | 1990-06-07 | 1997-03-25 | Banyu Pharmaceutical Co., Ltd. | Endothelin antagonistic substance |
| MY110439A (en) | 1991-02-07 | 1998-05-30 | Ishihara Sangyo Kaisha | N-phenylcarbamate compound, process for preparing the same and biocidal composition for control of harmful organisms |
| JPH05163221A (ja) | 1991-12-17 | 1993-06-29 | Fujirebio Inc | オキシ酸誘導体 |
| CA2071621C (en) * | 1991-06-19 | 1996-08-06 | Ahihiko Hosoda | Aldehyde derivatives |
| TW217417B (enExample) * | 1991-12-04 | 1993-12-11 | Manyu Seiyaku Kk | |
| WO1996011927A1 (en) * | 1994-10-12 | 1996-04-25 | Abbott Laboratories | Endothelin antagonists |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US6096758A (en) | 1996-01-26 | 2000-08-01 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 3-methylimidazopyridines |
| WO1999012534A1 (en) | 1997-09-10 | 1999-03-18 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
| GB9909409D0 (en) | 1999-04-24 | 1999-06-23 | Zeneca Ltd | Chemical compounds |
| BR0013666A (pt) * | 1999-08-27 | 2002-05-14 | Cytovia Inc | "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso |
| DE60004685T2 (de) | 1999-09-17 | 2004-07-29 | Abbott Gmbh & Co. Kg | Pyrazolopyrimidine als arzneimittel |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| US20030207876A1 (en) | 2000-06-23 | 2003-11-06 | Banks Bernard Joseph | 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy |
| DE10063008A1 (de) * | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| US7312247B2 (en) | 2001-03-27 | 2007-12-25 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| DE10247226A1 (de) | 2002-10-10 | 2004-04-22 | Merck Patent Gmbh | Heterocyclische Amide |
| WO2005079300A2 (en) | 2004-02-13 | 2005-09-01 | Albert Einstein College Of Medicine Of Yeshiva University | Protein kinase inhibitors and methods for identifying same |
| WO2006037468A1 (en) | 2004-09-30 | 2006-04-13 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv reverse transcriptase inhibitors |
| CA2593264C (en) | 2005-01-19 | 2012-09-25 | Merck & Co., Inc. | Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| WO2008075077A1 (en) | 2006-12-21 | 2008-06-26 | Astrazeneca Ab | Piperidine derivatives for the treatment of obesity |
| US20120177632A1 (en) * | 2011-01-10 | 2012-07-12 | Shinohara Mari L | Methods of optimizing disease treatment |
| US20120258967A1 (en) | 2011-03-09 | 2012-10-11 | Avila Therapeutics, Inc. | Pi3 kinase inhibitors and uses thereof |
| US9029548B2 (en) | 2011-05-06 | 2015-05-12 | Catabasis Pharmaceuticals, Inc. | Fatty acid lenalidomide derivatives and their uses |
| US9282738B2 (en) | 2011-07-11 | 2016-03-15 | Wisconsin Alumni Research Foundation | Antimicrobial compositions and methods of use thereof |
| WO2014081856A2 (en) | 2012-11-20 | 2014-05-30 | Azzazy Hassan | Ligands that target hcv-e2 binding sites on cd81 and therapeutic methods using them |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| WO2015077451A1 (en) | 2013-11-21 | 2015-05-28 | Allergan, Inc. | Phenylcarbamate derivatives as formyl peptide receptor modulators |
| FR3015483B1 (fr) | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| US20180008629A1 (en) | 2015-01-29 | 2018-01-11 | Yale University | Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders |
| AU2016222278B2 (en) | 2015-02-16 | 2020-07-09 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Sulfonylureas and related compounds and use of same |
| US20170001953A1 (en) | 2015-07-04 | 2017-01-05 | Mark Quang Nguyen | Fumarate compounds, pharmaceutical compositions thereof, and methods of use |
| GB2561540A (en) | 2017-03-13 | 2018-10-24 | Nodthera Ltd | Chemical compounds |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| EP3914351A1 (en) | 2019-01-25 | 2021-12-01 | Nodthera Limited | Carbamate derivatives and uses thereof |
-
2017
- 2017-07-31 GB GBGB1712282.1A patent/GB201712282D0/en not_active Ceased
-
2018
- 2018-07-31 HU HUE18755728A patent/HUE065337T2/hu unknown
- 2018-07-31 CA CA3070515A patent/CA3070515A1/en active Pending
- 2018-07-31 US US16/635,374 patent/US12247011B2/en active Active
- 2018-07-31 RS RS20240024A patent/RS65100B1/sr unknown
- 2018-07-31 HR HRP20231690TT patent/HRP20231690T1/hr unknown
- 2018-07-31 PT PT187557285T patent/PT3661921T/pt unknown
- 2018-07-31 PL PL18755728.5T patent/PL3661921T3/pl unknown
- 2018-07-31 FI FIEP18755728.5T patent/FI3661921T3/fi active
- 2018-07-31 MX MX2020001218A patent/MX2020001218A/es unknown
- 2018-07-31 EP EP18755728.5A patent/EP3661921B1/en active Active
- 2018-07-31 AU AU2018311198A patent/AU2018311198B2/en active Active
- 2018-07-31 DK DK18755728.5T patent/DK3661921T3/da active
- 2018-07-31 SM SM20240006T patent/SMT202400006T1/it unknown
- 2018-07-31 LT LTEPPCT/EP2018/070799T patent/LT3661921T/lt unknown
- 2018-07-31 EA EA202090419A patent/EA202090419A1/ru unknown
- 2018-07-31 WO PCT/EP2018/070799 patent/WO2019025467A1/en not_active Ceased
- 2018-07-31 TW TW107126572A patent/TWI810198B/zh active
- 2018-07-31 KR KR1020207005819A patent/KR102704546B1/ko active Active
- 2018-07-31 CN CN201880063698.8A patent/CN111356680B/zh active Active
- 2018-07-31 SG SG11202000325UA patent/SG11202000325UA/en unknown
- 2018-07-31 JP JP2020505150A patent/JP7357602B2/ja active Active
- 2018-07-31 IL IL272052A patent/IL272052B2/en unknown
- 2018-07-31 SI SI201831042T patent/SI3661921T1/sl unknown
- 2018-07-31 ES ES18755728T patent/ES2968669T3/es active Active
- 2018-07-31 BR BR112020001713-2A patent/BR112020001713A2/pt unknown
-
2020
- 2020-01-22 ZA ZA2020/00425A patent/ZA202000425B/en unknown
-
2023
- 2023-06-08 JP JP2023094466A patent/JP2023116627A/ja not_active Withdrawn
-
2025
- 2025-01-08 US US19/013,053 patent/US20250223263A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529405A5 (enExample) | ||
| JP7738910B2 (ja) | 置換ピリダジン化合物 | |
| HRP20231690T1 (hr) | Selektivni inhibitori nlrp3 inflamasoma | |
| RU2018121946A (ru) | Модуляторы ror-гамма | |
| HRP20241159T1 (hr) | Heterociklički agonisti za glp-1 | |
| ES2394963T3 (es) | Nuevos derivados de benzofenona o sales de los mismos | |
| JP2013518881A5 (enExample) | ||
| RU2017134551A (ru) | Новые дигидропиридоизохинолиноны и их фармацевтические композиции для лечения воспалительных расстройств | |
| JP2020537657A5 (enExample) | ||
| ES2343316T3 (es) | Derivados de piridina inhibidores de la cox-2. | |
| JP2013525458A5 (enExample) | ||
| JP2016500661A5 (enExample) | ||
| RU2019142795A (ru) | Производное n-(азаарил)циклолактам-1-карбоксамида, метод его получения и его применение | |
| JP2011510068A5 (enExample) | ||
| JP2015517579A5 (enExample) | ||
| JP2016532669A5 (enExample) | ||
| JP2014509647A5 (enExample) | ||
| HRP20160462T1 (hr) | Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1, cx3cr1 | |
| JP2013518888A5 (enExample) | ||
| JP2018515492A5 (enExample) | ||
| CN111655678A (zh) | 细胞凋亡信号调节激酶-1抑制剂及其应用 | |
| JP2011503081A5 (enExample) | ||
| JP2017508795A5 (enExample) | ||
| JP2013528619A5 (enExample) | ||
| JP2018510131A5 (enExample) |